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Abstract: Viruses have evolved efficient strategies to
overcome cellular membranes and transfer nucleic
acid into a host cell. This property is being exploited
in gene therapy which has the goal of delivering
therapeutic genes into a patient tissue in order to
achieve a clinically relevant effect. An interesting
target for virus-mediated gene transfer is the
immune system. In fact, the first human gene thera-
py trial performed involved the implantation of
autologous bone marrow cells transduced ex vivo
with gamma retrovirus vectors expressing adenosine
deaminase in a patient with severe combined
immunodeficiency. More recently, targeting trans-
gene expression to dendritic cells (DCs) has become
a promising strategy for directing the immune sys-
tem towards immunity or tolerance. DC targeting
has been achieved on a transcriptional level by using
DC-specific promoters or by retargeting the tropism
of the virus vectors. For example, we and others
have developed strategies that support antigen-spe-
cific immune tolerance by transducing hematopoiet-
ic stem cells with lentivirus- or gamma retrovirus-
vectors that transcriptionally target antigen expres-
sion to DCs. This review discusses the state of the art
of vector-targeting to DCs in preclinical as well as
clinical trials. [Discovery Medicine 20(109):145-151,
September 2015]
Introduction
The immune system is constantly occupied with fight-
ing and ultimately defeating pathogens, eliminating
tumors, and re-establishing homeostasis. To avoid
autoimmune disease, immune suppression mechanisms
have to be in place to prevent the immune system from
overreacting. In this context, dendritic cells play an
important role in capturing and presenting antigens to T
cells to induce immunity on one hand, and immune tol-
erance on the other hand.
The DCs are the most efficient professional antigen-
presenting cells (APC) due to many features that con-
tribute to regulating the immune system including (i)
high levels of MHC class I and class II molecules that
are constitutively synthesized; (ii) expression of acces-
sory molecules responsible for T cell adhesion (ICAM-
1) and co-stimulation (CD40, CD80 and CD86)
(Scheeren et al., 1991; Larsen et al., 1992; Young et al.,
1992); (iii) production of immunostimulatory cytokines
that are up-regulated after recognition of pathogen-
associated molecule patterns (PAMPs) or through
endogenous signals released by dying cells; (iv) capa-
bility of migrating from inflamed tissue to lymph nodes
due to down regulation of chemokine receptors such as
CCR6 and CCR5 which are responsible for peripheral
tissue localization and recruitment to inflamed sites,
respectively (Luster, 2002), and up-regulation of CCR7
(Randolph et al., 2005) or CCR2 (CCR7-independent
pathway) (Nakano et al., 2009) in monocyte-derived
DCs and CCR8 in skin-derived DCs that allows their
entry into lymph nodes (Randolph et al., 2005). (v) In
addition, DCs are the most efficient APCs in cross-pre-
senting exogenous antigens via MHC I to CD8+ T cells
(den Haan et al., 2000; Heath et al., 2004; Joffre et al.,
2012). This process favours cytotoxic T lymphocyte
(CTL) activation against viral infections and tumor
cells.
Indeed, for decades DCs have been considered highly
effective tools for inducing robust and specific thera-
peutic immune modulation. A well-established
approach of loading autologous DCs in vitro with
tumor-specific peptides before re-injecting them into
recipient organisms generated promising results both in
pre-clinical trials in mice (Badovinac et al., 2005; Hira
et al., 2015) as well as in human phase I/II trials with
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proven safety (Nestle et al., 1998; Dillman et al., 2012;
Wang et al., 2015). The in vitro transduction of autolo-
gous DCs with viral vectors to “load” DCs with antigen
has also resulted in efficient induction of antigen-spe-
cific cellular and humoral immune responses (Brossart
et al., 1997; Song et al., 1997). Despite the promising
results obtained from ex vivo manipulation of DCs, iso-
lation and expansion of these cells is time consuming,
laborious and the overall costs are high. Moreover, ther-
apeutic effects of antigen-pulsed DCs would be restrict-
ed to patient’s HLA and would depend on tumor avail-
ability (Jenne et al., 2001). Therefore, other approaches
such as in vivo DC targeting or manipulation of DC-
progenitors would be highly desirable. In this review
we discuss promising strategies for targeting DCs with
viral vectors in order to modulate the immune system.
Targeting DCs with Viral Vectors to Induce
Immunity
The approach of using viral vectors to deliver genetic
material into a cell and regulate the immune system has
made significant progress in the last years. One of the
advantages of using viral vectors for genetically modi-
fying DCs is the concomitant induction of DC matura-
tion (Schumacher et al., 2004). Human DCs transduced
with recombinant adenovirus vectors for example up-
regulate CD83 and down-regulate CD14, characterizing
a mature phenotype, and the cells also down-regulate
IL-10 production (Schumacher et al., 2004). A detailed
description of the molecules involved in DC activation
is found elsewhere (Apostolopoulos et al., 2013). The
biggest challenge faced by in vivo transduction of DCs
with viral vectors is targeting specific cells to assure
safety and efficacy of immunization and reducing
adverse effects in the surrounding cells. To achieve spe-
cific cell targeting, natural virus surface molecules
(membrane glycoproteins, capsid proteins) are manipu-
lated to create, enhance or eliminate the affinity to a
specific cellular receptor. Cell surface receptors for tar-
geting antigens to DCs include the C-type lectin recep-
tors (DC-SIGN, DEC-205, dectins, mannose receptors),
Toll-like receptors (TLRs) and other pattern recognition
receptors (Palucka and Banchereau, 2012;
Apostolopoulos et al., 2013).
The most important viruses that have been used as vec-
tors in gene therapy protocols include adenovirus,
adeno-associated virus, herpesvirus, poxvirus, and
retrovirus (both standard gamma retroviruses and
lentiviruses). These viruses transduce different cell
types but can also be pseudotyped to redirect virus tro-
pism. Here we discuss the state of the art of vector-tar-
geting to DCs in preclinical as well as in clinical trials.
Induction of Immune Responses with Adenovirus
Vector-modified DCs
Adenoviruses are non-enveloped, double-stranded
DNA viruses with a transgene capacity of 7-35 kb. The
virus genome is easily manipulated, and vector produc-
tion yields high titers. Adenovirus vectors have been
used in a wide range of clinical trials for inducing
immune responses, including cancer vaccination
approaches. The immunosuppressive tumor microenvi-
ronment results in poor activation of the immune sys-
tem due to increased numbers of regulatory T cells and
myeloid-derived suppressor cells, high levels of
immunosuppressive cytokines, and induction of tumor
antigen specific CD4+ and CD8+ T cell tolerance
(Rabinovich et al., 2007; Shiao et al., 2011). Targeting
tumor antigens to DCs may enhance tumor-specific
effector T cell immune responses. However, the gener-
ation of a tumor-specific immune response has not
always reflected in clinical response and improvement
of clinical effects remains a challenge (Butterfield et
al., 2008; Chia et al., 2012).
In a pilot phase I/II therapeutic vaccination strategy,
patients with chronic hepatitis C virus infection
received two doses of autologous monocyte derived
DCs transduced with adenovirus vector (Zabaleta et al.,
2015). The recombinant adenovirus vector encoded the
hepatitis C virus NS3 protein and a chimeric molecule
consisting of the coxsakie and adenovirus receptor
(CAR) fused to the ectodomain of CD40L (CFh40L),
enhancing DC transduction and maturation.
Vaccination showed no side effects but the immune
responses generated against NS3 protein were poor and
not sufficient to control hepatitis C virus infection. T
cell exhaustion has already been described in hepatitis
C virus infected patients (Sumida et al., 2013) and may
be an explanation for the lack of NS3-specific T cell
priming. Future trials should also consider the impact of
the adapter CFh40L that appears to increase IL-10-pro-
duction by DCs. IL-10 may be involved in down regu-
lating hepatitis C virus-directed cellular immune
response (Zabaleta et al., 2015).
The low magnitude of antigen specific immunity
induced by recombinant adenovirus vector transduced
DCs highlights the importance of employing molecules
that boost immune responses. A successful approach to
enhance antigen delivery to DCs consists of linking
antigen to monoclonal antibodies that specifically bind
to DC receptors involved in antigen uptake. Indeed, in
animal models (Idoyaga et al., 2011; Flacher et al.,
2012) and ex vivo human cells (Dakappagari et al.,
2006) or tissue (Stoitzner et al., 2014) it has been well
established that targeting DC receptors such as
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DEC205, Dectin-1, Langerin and other DC-specific
molecules increases antigen uptake and presentation.
Mice immunized with a replication-defective aden-
ovirus vector encoding ovalbumin (OVA) fused to a
DEC205-specific antibody resulted in enhanced CD8+
T cell proliferation and IgG production (Tenbusch et al.,
2013). High doses of adenovirus vectors expressing
OVA-DEC205 induced also CD4+ T cell responses that
were not observed after vaccination with the adenovirus
vectors encoding only OVA.
Induction of Immune Responses with Gamma
Retrovirus Vectors
Retroviruses are enveloped, single-stranded RNA virus-
es that are able to integrate into the host cell genome as
a provirus. With a transgene capacity of 7.5kb, retro-
viruses are among the viral vectors most frequently
used in clinical trials, gamma retrovirus vectors in par-
ticular and more recently also lentivirus vectors. Studies
that applied gamma retrovirus vectors in animal models
and in human patients have shown promising results in
ameliorating several genetic diseases, including X-
linked severe combined immunodeficiency disorder (X-
SCID) (Hacein-Bey-Abina et al., 2010), b-thalassemia
(Negre et al., 2011), Wiskott-Aldrich syndrome (Aiuti
et al., 2013) and metachromatic leukodystrophy (Biffi
et al., 2013). Moreover, gamma retrovirus vector trans-
duced hematopoietic stem cells (HSCs) have been
shown to induce immune tolerance in animal models of
autoimmune disorders (Xu et al., 2006; Chan et al.,
2008; Eixarch et al., 2009). However, the limitation of
using retroviruses in gene therapy is the risk of inser-
tional mutagenesis. In fact, random genomic integration
was demonstrated in a clinical trial for X-linked severe
combined immunodeficiency disorder (X-SCID) in
which 5 out of 20 patients developed leukaemia
because of activation of the oncogene LMO2 (Howe et
al., 2008; Hacein-Bey-Abina et al., 2010). It is still not
known if the mutation occurred due to viral sequences
or due to the transgene itself. In X-SCID patients the g-
chain of the IL-2 receptor (IL2RG) is mutated. The
retrovirus vectors were used to restore the expression of
the IL2RG. According to Woods et al. (2006), the pro-
liferative disorder of the T cells was caused rather by
the IL2RG gene itself than by genomic insertion of the
vector DNA. This conclusion was based on mouse
experiments which showed that X-SCID mice devel-
oped T cell lymphomas after receiving HSCs trans-
duced with lentivirus vectors carrying the murine
IL2RG transgene, while control mice reconstituted with
HSCs transduced with a control lentivirus vector did
not (Woods et al., 2006)176.
In contrast to gamma retroviruses, lentiviruses integrate
preferentially in transcriptionally activate loci, thereby
reducing the risk of proto-oncogene activation
(Schröder et al., 2002). In addition, several modifica-
tions to the vectors have improved their safety profile.
For example, self-inactivating (SIN) lentivirus vectors
were constructed by deleting the promoter and enhancer
elements from the U3 region of the viral genome, gen-
erating a replication-incompetent virus (Miyoshi et al.,
1998). The deletion of the viral promoter allows the
insertion of cell type-specific promoters that support
transgene expression in specific cells and are therefore
less likely to be silenced, thus improving transduction
efficiency and safety of vectors. Moreover, as opposed
to gamma retroviruses, lentiviruses can efficiently
transduce not only dividing but also non-dividing cells
including HSCs, which constitutes a major advantage
particularly also for manipulating the immune system,
as discussed in the following section.
Induction of Immune Responses with Lentivirus
Vector-modified DCs
Because of the aforementioned properties, lentivirus
vectors have been favoured over gamma retrovirus vec-
tors in recent years. The sindbis virus envelope protein
has been used for lentivirus vector pseudotyping to tar-
get DCs. Sindbis virus envelope glycoproteins recog-
nize and bind preferentially to the DC-SIGN (CD209)
surface molecule that is expressed mainly by immature
and mature DC subpopulations (Geijtenbeek et al.,
2000). However, sindbis virus envelope glycoprotein
E2 can also bind to heparan sulphate (HS) which is
present on the surface of many different cells. Yang et
al. (2008) showed that more specific DC targeting can
be achieved by deleting the HS binding site of E2. After
subcutaneous injection in mice, pseudotyped lentivirus
vectors efficiently transduced DCs, supported the
migration of activated DCs to regional lymph nodes,
and induced antigen-specific cellular immune response
(Yang et al., 2008). Another approach to retarget
lentivirus vectors to APCs consists of fusing single-
chain antibodies that bind to MHC-II molecules with
envelope proteins of the vector particles. Such vectors
can efficiently activate CD8+ T cells in mice (Gennari
et al., 2009).
In a cancer vaccination approach in mice, subcutaneous
injection of lentivirus vectors expressing tumor-associ-
ated antigens or, as control, ovalbumin resulted in the
efficient transduction of DCs in vivo. Moreover, trans-
duced DCs were found in the draining lymph nodes and
in the spleen, and induced antigen-specific CD8+
(Esslinger et al., 2003; Dullaers et al., 2006) and CD4+
T cell responses (Dullaers et al., 2006). Anti-tumor-spe-
cific immune responses also contributed to tumor
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growth inhibition and prolonged survival of the animals
after challenge (Dullaers et al., 2006).
Transgene expression levels should also be considered
when choosing a strategy to target DCs. Although the
dendritic cell-associated C-type lectin, the dectin-2 pro-
moter, restricts transgene expression to Langerhans
cells in the skin and CD11c+ populations in the lymph
nodes and induces antigen-specific CD8+ and CD4+ T
cell responses in mice, the low levels of transgene
expression can compromise therapeutic effects (Lopes
et al., 2008).
A promising approach is to genetically modify and
reprogram DC precursors by lentivirus vectors. In that
context, murine HSCs have been transduced in vitro
with a tricistronic lentivirus vector that co-expresses
granulocyte macrophage colony stimulating factor
(GM-CSF), interleukin 4 (IL-4) and the herpes simplex
virus-thymidine kinase (HSV-TK) gene (Pincha et al.,
2011; 2012). The co-expression of GM-CSF and IL-4
by vector-transduced HSCs was used to drive in vitro
cell-differentiation into self-differentiated myeloid-
derived antigen-presenting-cells reactive against
tumors (SmartDCs) while the suicide gene HSV-TK
allowed in vivo depletion of transduced cells upon gan-
ciclovir treatment. SmartDCs transduced with viral
vectors that encoded melanoma related antigen induced
therapeutic improvement in mice with reduced tumor
growth and higher survival rate compared to the control
group (Pincha et al., 2011).
Induction of Immune Tolerance by Virus Vector-
modified DCs 
DCs have not only the function to boost an immune
response, but also to shut it down when over-reactive
(Figure 1). Injection of immature blood monocyte pre-
cursor derived DCs pulsed in vitro with antigens into
two healthy volunteers resulted in antigen specific cel-
lular immune tolerance characterized by a decrease of
IFNg-producing T cells and an increase of IL-10-pro-
ducing T cells in a small randomized study (Dhodapkar
et al., 2001). However, using virus vectors for targeting
antigen presentation to DCs without inducing DC stim-
ulation/maturation can be challenging. Conflicting
results have indeed been published regarding induction
of DC maturation by lentivirus vectors (Gruber et al.,
2000; Breckpot et al., 2007; Toscano et al., 2010). In a
recent study it was demonstrated that lentivirus vectors
induced maturation of plasmacytoid DCs while the
phenotype of myeloid DCs and in vitro differentiated
monocyte-derived DCs was not altered (Rossetti et al.,
2011). Using a lentivirus vector expressing vasoactive
Figure 1. Current protocols for physically or transcriptionally targeting transgene expression to DCs. (a) In vivo DC
targeting by direct injection of virus vectors to boost antigen-specific immune responses. (b) Injection of hematopoiet-
ic stem cells (HSCs) transduced in vitro with virus vectors to induce antigen-specific immune tolerance. (c and d)
Injection of HSC-derived DCs or peripheral blood mononuclear cell (PBMC)-derived DCs transduced in vitro with viral
vectors to induce (c) immunity or (d) tolerance, depending on co-expression of stimulatory or suppressive signals.
149
Discovery Medicine, Volume 20, Number 109, September 2015
Novel Immunotherapeutic Approaches in Targeting dCs with Virus Vectors
intestinal peptide (VIP) that has immune suppressive
activity, Toscano et al. (2010) showed that mice inject-
ed with myelin protein loaded lentivirus vector-trans-
duced BM-derived DCs were protected from experi-
mental autoimmune encephalomyelitis (EAE).
Furthermore, in an asthma model in mice, bone marrow
(BM)-derived DCs transduced with recombinant
lentivirus vectors encoding OVA antigen and IL-10
were able to induce OVA-specific immune tolerance
(Henry et al., 2008).
Considering that the therapeutic effect of DCs trans-
duced ex vivo with lentivirus vectors will be restricted
by the life span of those cells, a feasible approach to
induce long-term expression of specific antigens by
steady state DCs is the manipulation of DC progenitors,
the HSCs.
In this context, our group and others demonstrated that
the transduction of HSCs with SIN-lentivirus vectors
(De Andrade Pereira et al., 2013; 2015) or SIN-gamma
retrovirus vectors (Ko et al., 2011) resulted in efficient
antigen-specific immune tolerance in mice.
Although, lentivirus vectors are more efficient in trans-
ducing quiescent cells (Naldini et al., 1996) such as
HSCs, targeting myelin oligodendrocyte glycoprotein
(MOG) expression to dendritic cells with a gamma
retrovirus vector significantly delayed the onset of
EAE in mice compared to controls (Ko et al., 2011). In
this study MOG was under transcriptional control of a
960bp fragment of the CD11c promoter (-960 to +51
bp) and the transgene was expressed indeed predomi-
nantly in CD11c+ MHC-II+ DCs. Absence of protec-
tion from EAE in that study could be related to low
level of antigen expression due to the promoter or inef-
ficient transduction of HSCs or both.
In order to restrict transgene expression to DCs, our
group transduced BM-derived HSC with a SIN-
lentivirus vector that expresses MOG under transcrip-
tional control of the DC-specific transmembrane pro-
tein (DC-STAMP) promoter (Figure 2). The DC-
STAMP promoter resulted in transcriptional targeting
of transgene expression mainly to DCs (De Andrade
Pereira et al., 2013). All mice, which received HSCs
transduced with this vector were fully protected from
EAE induced either by immunization with myelin anti-
gen (De Andrade Pereira et al., 2013) or by transfer of
myelin antigen-reactive T cells (De Andrade Pereira et
al., 2015). Protection was concomitant with the gener-
ation of MOG-specific regulatory CD4+ T cells and
depletion of MOG-specific CD4+ T cells (De Andrade
Pereira et al., 2013). Importantly, tolerance was
induced towards the specific self-antigen MOG while T
cell reactivity to unrelated foreign antigens was fully
preserved.
The adoptive transfer of myelin antigen-reactive T cells
resulted also in the complete protection of tolerized
animals from EAE, while non-tolerized mice rapidly
developed disease symptoms (De Andrade Pereira et
al., 2015). Tolerance induction correlated with the up-
regulation of molecules associated with T cell anergy
and regulatory T cell phenotype. The ability to revert
the pathogenic phenotype of MOG-specific CD4+ T
cells highlights the potential of this strategy as a thera-
peutic approach in an established autoimmune disease.
In our study, animals that received lentivirus vector
transduced HSCs continued to produce MOG-express-
ing, tolerizing DCs for up to six months after transplan-
tation (De Andrade Pereira et al., 2013). However,
long-term transgene expression in human DCs remains
to be assessed. In case of transgene silencing, modifi-
cations to the vector, such as the incorporation of scaf-
Figure 2. Induction of antigen-specific immune tolerance by lentivirus vector-transduced BM-HSC in an experimental
autoimmune encephalomyelitis (EAE) model. HSCs are collected from 5-fluorouracil (5-FU) treated C57BL/6 donor
mice and cultured in presence of cytokines. After three days HSCs are transduced with lentivirus vector and transplant-
ed into lethally irradiated C57BL/6 recipient mice. Six to eight weeks after transplantation chimeras are challenged by
immunization with myelin antigen or injection of activated myelin-reactive CD4+ T cells and between 7 and 14 days
later analyzed for tolerance induction.  
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fold/matrix attachment regions or insulators to diminish
the suppressive effect of nearby heterochromatin may
be considered (Ramezani and Hawley, 2010).
Ongoing Clinical Trials Using Autologous DCs for
Inducing Immune Responses 
In most of the ongoing clinical trials DCs are modified
ex vivo with non-viral methods, including peptide load-
ing and mRNA transfection (Table 1). In fact, to this
date, Provenge (Sipuleucel-T), a treatment for metasta-
tic prostate cancer, is the only product based on autolo-
gous DCs that received marketing authorisation by the
Food and Drug Administration (FDA). The treatment
consists of culturing and activating peripheral-blood
mononuclear (PBMC) APCs from patients with recom-
binant prostate protein (prostatic acid phosphatase)
fused to GM-CSF (Kantoff et al., 2010a). In a double-
blind, phase III trial, survival rate was prolonged in an
average of 4.1-months in cancer patients treated with
Sipuleucel-T as compared with the group that received
placebo (Kantoff et al., 2010a).
Table 1. Overview of DC-based Clinical Trials.
Vehicle Antigen Disease Phase Status
mRNA-transfected autologous DCs Autologous HIV mRNA transcripts Chronic HIV infection I/II C
mRNA encoding gp100 and tyrosinase Uveal melanoma I/II R
Antigen loaded autologous DCs Heat-inactivated autologous HIV HIV infection1 II C
Autologous tumor antigens Sarcoma I/II R
Melanoma III R
Metastatic colorectal
neoplasm
II C
Brain tumor II C
Advanced melanoma I/II C
HIV-1 Lipopeptides; DC activation
with LPS
HIV-1 infected patients I C
DEC-205/NY-ESO-1 fusion protein
with or without rflt3 ligand 
NY-ESO-1 & neoantigen-based
melanoma2
Stage IIB-IV melanoma II R
DEC-205/NY-ESO-1 fusion protein
and IDO1 inhibitor
DEC-205/NY-ESO-1 Fusion Protein
CDX-1401
Cancer in remission3 I/II R
Note: 1, very early stages of the disease; 2, neoantigen-based melanoma-poly-ICLC; 3, ovarian, fallopian tube or primary peritoneal can-
cer.
Abbreviations: C, completed; R, recruiting; DEC-205, endocytosis-mediating C-type lectin receptor; HIV, human immunodeficiency
virus; gp, glycoprotein.
Table 2. Overview of DC-based Clinical Trials Using Virus Vectors.
Vehicle Antigen Disease Phase Status
Direct injection of adenovirus vector GM-CSF Non muscle invasive bladder cancer II/III O, NR
Direct injection of hybrid lentivirus
vector (sindbis virus envelope)
NY-ESO-1 Advanced or metastatic cancer1 I O, R
Autologous DCs transduced with
adeno-associated virus vector
CEA IV Gastric cancer I O, NR
Autologous DCs transduced with
adenovirus vector
CAIX fused to GM-CSF Metastatic kidney cancer I O, R
NS3 HCV patients I/II C
Her-2 Metastatic breast cancer I C
p53 Extensive-stage small cell lung cancer I/II C
Autologous DCs transduced with
vaccinia- or fowlpox virus vector
MUC-1 Liver/lung metastases from colorectal
cancer
II C
Note: 1, melanoma, sarcoma, ovarian, breast, bladder or non-small cell lung cancer.
Abbreviations: O, ongoing; C, completed; R, recruiting; CAIX, Carbonic anhydrase IX; GM-CSF, Granulocyte-macrophage colony-stim-
ulating factor; CEA, Carcinoembryonic antigen; CSF, cerebrospinal fluid; NS3, Nonstructural protein 3; HCV, Chronic hepatitis C virus;
Her-2, human epidermal growth factor receptor 2; MUC-1, mucin 1. 
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However, although not yet FDA approved therapies,
there are several ongoing clinical trials that use virus
vector transduced DCs for inducing immune responses
(Table 2 and https://clinicaltrials.gov). For example, in
a phase II randomized trial metastatic prostate cancer
patients received a single dose of vaccinia virus vector
followed by six boosts of fowlpox virus vectors both
expressing a prostate-specific antigen and co-stimulato-
ry molecules (CD80, ICAM-1 and LFA-3) (Kantoff et
al., 2010b). All injections were accompanied by GM-
CSF as an adjuvant. Control groups received empty
viral particles. Survival improvement was observed in
treated patients in a median rate of 8.5 months pushing
the study forward to a phase III ongoing trial (clinical
trial identifier number NCT01322490).
Another study in metastatic kidney cancer patients cur-
rently under phase I, involves autologous DCs trans-
duced with a recombinant adenovirus vector encoding
GM-CSF fused with a kidney cancer-associated antigen
(AdGMCAIX; clinical trial identifier number
NCT01826877). The efficiency of this approach was
previously demonstrated in animals, in which mice
transplanted with vector transduced DCs generated
antigen-specific T cell immune responses and showed
tumor growth inhibition (Birkhäuser et al., 2013).
An ongoing phase I trial in advanced and metastatic
cancer patients uses sequential and direct injection of an
integration-deficient hybrid lentivirus vector targeting
the DC-SIGN receptor through sindbis virus envelope
glycoprotein pseudotyping and expressing a highly
immunogenic tumor antigen NY-ESO-1 and a second
injection of full length NY-ESO-1 protein together with
a TLR4 agonist (clinical trial identifier number
NCT02387125). This approach has the advantage that it
avoids ex vivo manipulation of patient cells.
Conclusion 
Many studies in animal models demonstrated the poten-
tial of DCs for either enhancing antigen specific cellu-
lar immune responses or immune tolerance. Clinical tri-
als in human patients with antigen-pulsed-, mRNA
transfected- or virus vector modified DCs proved safe
and were associated with only mild side effects. Recent
studies showed that clinical improvement may be
achieved by combining DC transduction with
immunomodulation. For cancer treatment for example,
antigen expression/presentation by DCs could be com-
bined with blocking of negative regulatory molecules
such as PD1/PDL1 and CTLA-4 in order to circumvent
T cell exhaustion and induce an efficient tumor specif-
ic immune response (Metcalfe et al., 2015). When the
aim is to induce a broad immune response against sev-
eral antigens in an HLA-independent manner, virus
vectors would be the prime choice. DCs modified by
viral vectors expressing full-length proteins activate not
only CD4+ T cells but induce also antigen cross-presen-
tation to CD8+ T cells. In an autoimmune context, the
strategy of expressing full-length protein as antigen
may allow to induce immune tolerance against multiple
epitopes and avoid epitope spreading. A gene therapy
approach that combines the genetic modification of
DCs with virus vectors and the manipulation of HSCs
may efficiently induce self-protein tolerance in absence
of generalized immunosuppression. Future strategies
for livelong interventions in the immune system in
genetic and autoimmune diseases should consider tar-
geting virus vectors physically to HSCs but transcrip-
tionally to DCs. However, the long-term effects of tar-
geting DCs with virus vectors are unknown and should
be considered with caution.
Recent pre-clinical and clinical trials using virus vector-
modified DCs for regulating the immune system have
yielded promising results. Nevertheless, there is still
room for optimizations concerning DC targeting as well
as the induction of potent antigen-specific immune
responses while avoiding vector specific host respons-
es. Moreover, vector safety may be improved by incor-
porating suicide genes that allow the elimination of vec-
tor transduced cells in case of adverse effects.
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